In another move to bolster its anti-infective pipeline, Basilea has agreed to acquire anti-fungal, fosmanogepix, from Ampylyx Pharmaceuticals, an affiliate of Pfizer. Through the deal, which is worth up to US$147 M, Basilea gains rights to the potential first-in-class antifungal currently in Phase II studies for the treatment of Candidemia, including Candida auris, and invasive mould infections. The agreement comes at a time where Basilea is looking to reorganise its R&D pipeline, focusing on anti-infectives and pivoting away from its oncology pipeline.